Stem cell culture supernatant and exosomes

幹細胞培養上清液・エクソソーム / Stem cell culture supernatant and exosomes

After stem cells are cultured, the liquid left once the cells are removed is called supernatant. It contains proteins the cells secreted and exosomes (extracellular vesicles). It comes from other people's cells and contains no cells itself, so it is not regenerative medicine as Japanese law defines it and is not bound by the provision plan system.

At a glance

Legal classification
Outside the Act on the Safety of Regenerative Medicine (as of November 2026)
Source of the cells
Liquid from culturing other people's stem cells: fat, bone marrow, umbilical cord, dental pulp and others
Visits needed
Done in a day each time; often sold as a course of several
Culture time
None
Planning your stay
You leave the same day

What it is used for

  • Offered at Japanese clinics by drip, injection, nasal spray or skin delivery, mostly for beauty and anti-aging
  • Claims often seen in promotion, such as repairing nerves, preventing stroke or rejuvenating the whole body, have not been confirmed in clinical trials

How it is done

  1. Consultation

    The physician explains where the product comes from and the risks. This step cannot be skipped or left to a counselor.

  2. Checking the product

    Ask the clinic to show the product's source, manufacturing site and test reports.

  3. Administration

    Skin delivery, local injection, nasal spray or intravenous drip. The risk differs a great deal by route.

  4. Observation

    You are observed afterwards for allergic or other reactions.

The evidence so far

  • A health ministry notice of July 2024 states that no supernatant or exosome product, in Japan or abroad, has been shown effective and safe and approved as a medicine, and that physicians use them on their own responsibility
  • In December 2024 the Japanese Society for Regenerative Medicine warned the public that clinical evidence for treatment with iPS cell-derived exosomes is not established
  • Source cells, manufacturing methods, contents and concentrations differ between products, with no common standard
  • In July 2026 the health ministry began discussing whether to bring these treatments under the law. Papers for its 8 October meeting proposed bringing extracellular vesicles, including exosomes, under the regenerative medicine law; how supernatant will be treated is not yet settled

Risks

  • Allergic reactions, including anaphylactic shock in severe cases
  • Because the product comes from other people's cells, there is a risk of viral or other infection, depending on donor screening and manufacturing control
  • Uneven quality: the actual contents may not match the claims
  • Intravenous drip carries more risk than skin delivery or local use
  • If something goes wrong, there is no reporting and investigation system like the one under the regenerative medicine law

How we arrange it

  • We can arrange this kind of treatment, but only after the physician has seen you in person and explained where the product comes from and its risks.
  • Before booking, we ask the institution for the product's source, its manufacturing site and its test reports, and translate the key points for you. Where these are not provided, we do not arrange it.
  • The physician decides the route of administration. We ask the physician to explain why that route was chosen and whether a lower-risk one exists.
  • We do not repeat claims that lack clinical evidence, such as repairing nerves, preventing stroke or rejuvenating the whole body, and we promise no results.
  • After the consultation, you are free to decide against it.

Precautions

Before and after

  • Stay for observation as the clinic requires
  • Tell staff at once about a rash, breathing difficulty or palpitations
  • If you feel unwell after returning home, see a doctor and say you have had this product

When it is unsuitable or needs a physician's assessment

  • An allergic constitution or a history of severe allergy
  • Cancer under treatment or in your history: the effect of growth factors on tumors is unknown
  • Pregnancy or breastfeeding
  • Active infection

Questions to ask at the consultation

  • Where do the source cells come from, and what infection screening did the donor have?
  • Where is it made, and is there a sterility and virus test report for each batch?
  • Why this route of administration, and is there a lower-risk one?
  • What happens if there is an adverse reaction?
  • What is the basis for the claimed effects?

This page is general information based on what was public as of November 2026. Suitability is for the physician to judge at the consultation. Filing a provision plan is a procedural requirement and does not mean the state has confirmed that a treatment works.

All regenerative treatments

Tell us about your situation

The first consultation is free. Tell us what you are interested in, what you have had done before and when you would like to come. We reply within two business days.

Contact us